Why Bother with First-HD? Because We Need a "Better" Tetrabenazine
Posted December 3, 2013 by LaVonne Goodman M.D.
First-HD is a clinical trial testing SD-109 ER, a new extended-release form of tetrabenazine (Xenazine®). Finding the 90 participants, who must have moderately severe untreated chorea, has been difficult and slower than expected. Only 4 or 5 participants are needed for each of the 20 centers doing this trial. Why should we bother with this trial?
Because we will never have better medical treatments for ourselves -- or our children -- if we don't join this, and other clinical trials.
Posted November 4, 2013 by LaVonne Veatch Goodman, MD
A short while ago a patient
of mine died after a long struggle with Huntington's disease. Here I tell the uplifting story about him and the last four years of his life. This story would not have been the same -- for him or for me -- without Elizabeth, our mutual and ordinary/extraordinary friend.
Treatment Guidelines for Huntington's: Who needs them?
Posted by LaVonne Goodman M.D.
During my years as an internal medicine physician, I have used standard of care guidelines for my patients with conditions like diabetes and heart disease. Guidelines are developed by experts in each disease who
translate clinical trial evidence and/or expert experience into recommended care patterns
for use in medical offices or at the bedside. When followed, guidelines have been central to improving the
quality of care provided by all physicians whether they are specialists or